Market Cap 3.81M
Revenue (ttm) 670,000.00
Net Income (ttm) -7.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,176.12%
Debt to Equity Ratio 0.00
Volume 52,300
Avg Vol 238,246
Day's Range N/A - N/A
Shares Out 3.54M
Stochastic %K 79%
Beta 1.18
Analysts Strong Sell
Price Target $10.83

Latest News on CANF

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 11 months ago

Can-Fite Provides Namodenoson Patent Update


Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Reports 2023 Financial Results and Clinical Update